Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Cellular Oncology
Published in: Cellular Oncology 4/2017

01-08-2017 | Original Paper

MDMX is a prognostic factor for non-small cell lung cancer and regulates its sensitivity to cisplatin

Authors: Han Zhao, Yu-Zhuo Xie, Rui Xing, Ming Sun, Feng Chi, Yue-Can Zeng

Published in: Cellular Oncology | Issue 4/2017

Login to get access

Abstract

Purpose

Chemoradiotherapy is the standard treatment modality for advanced non-small cell lung cancer (NSCLC). However, drug and radiation resistance remain major factors influencing its clinical outcome. The purpose of this study was to evaluate whether MDMX can affect the chemosensitivity and clinical outcome of NSCLC.

Methods

Quantitative real-time PCR (qRT-PCR) was performed to assess MDMX mRNA expression levels in 105 primary NSCLC tissues, its corresponding non-cancerous tissues and two NSCLC-derived cell lines (A549 and SK-MES-1). In addition, immunohistochemistry was carried out to detect MDMX protein expression in the primary NSCLC tissues. The MDMX expression levels were correlated with clinicopathological and survival features. The effects of MDMX expression knockdown on NSCLC cell proliferation and chemosensitivity were evaluated using MTT, flow cytometry and soft agar colony assays.

Results

We found that the mRNA expression level of MDMX in NSCLC tissues was significantly higher than that in its corresponding non-tumorous tissues. High MDMX expression was found to be related to poor tumor cell differentiation, advanced TNM stages and the occurrence of lymph node metastases. Patients with a high MDMX expression level exhibited a lower overall survival rate than those with a low expression level. Multivariate analysis showed that a high MDMX protein expression level may serve as an independent prognostic factor for NSCLC patients. In addition, we found that MDMX expression knockdown combined with cisplatin treatment in vitro significantly increased apoptosis and decreased soft agar colony formation in NSCLC-derived cells.

Conclusions

Our data indicate that MDMX expression may serve as an independent unfavorable prognostic factor for NSCLC patient outcome, which in turn may at least partly be due to the ability of the MDMX protein to regulate the proliferative capacity and chemosensitivity of NSCLC cells.
Literature
1.
C.E. DeSantis, C.C. Lin, A.B. Mariotto, R.L. Siegel, K.D. Stein, J.L. Kramer, R. Alteri, A.S. Robbins, A. Jemal, Cancer treatment and survivorship statistics. CA Cancer J Clin 64, 252–271 (2014)
2.
M. Reck, D.F. Heigener, T. Mok, J.C. Soria, K.F. Rabe, Management of non-small-cell lung cancer: Recent developments. Lancet 382, 709–719 (2013)CrossRefPubMed
3.
L.E. Coate, T. John, M.S. Tsao, F.A. Shepherd, Molecular predictive and prognostic markers in non-small-cell lung cancer. Lancet Oncol 10, 1001–1010 (2009)CrossRefPubMed
4.
Y.X. Bao, X.D. Zhao, H.B. Deng, C.L. Lu, Y. Guo, X. Lu, L.L. Deng, Schedule-dependent cytotoxicity of sunitinib and TRAIL in human non-small cell lung cancer cells with or without EGFR and KRAS mutations. Cell Oncol 39, 343–352 (2016)CrossRef
5.
C.C. Koning, S.J. Wouterse, J.G. Daams, L.L. Uitterhoeve, M.M. van den Heuvel, J.S. Belderbos, Toxicity of concurrent radiochemotherapy for locally advanced non--small-cell lung cancer: A systematic review of the literature. Clin Lung Cancer 14, 481–487 (2013)CrossRefPubMed
6.
P. Chen, J. Li, Y.C. Chen, H. Qian, Y.J. Chen, J.Y. Su, M. Wu, T. Lan, The functional status of DNA repair pathways determines the sensitization effect to cisplatin in non-small cell lung cancer cells. Cell Oncol 39, 511–522 (2016)CrossRef
7.
Y.L. Chen, T.Y. Yang, K.C. Chen, C.L. Wu, S.L. Hsu, C.M. Hsueh, Hypoxia can impair doxorubicin resistance of non-small cell lung cancer cells by inhibiting MRP1 and P-gp expression and boosting the chemosensitizing effects of MRP1 and P-gp blockers. Cell Oncol 39, 411–433 (2016)
8.
R. Shavit, M. Ilouze, T. Feinberg, Y.R. Lawrence, Y. Tzur, N. Peled, Mitochondrial induction as a potential radio-sensitizer in lung cancer cells - a short report. Cell Oncol 39, 247–252 (2015)CrossRef
9.
A. Shvarts, W.T. Steegenga, N. Riteco, T. van Laar, P. Dekker, M. Bazuine, R.C. van Ham, W. van der Houven van Oordt, G. Hateboer, A.J. van der Eb, A.G. Jochemsen, MDMX: A novel p53-binding protein with some functional properties of MDM2. EMBO J 15, 5349–5357 (1996)PubMedPubMedCentral
10.
R. Stad, Y.F. Ramos, N. Little, S. Grivell, J. Attema, A.J. van Der Eb, A.G. Jochemsen, Hdmx stabilizes Mdm2 and p53. J Biol Chem 275, 28039–28044 (2000)PubMed
11.
12.
D. Danovi, E. Meulmeester, D. Pasini, D. Migliorini, M. Capra, R. Frenk, P. de Graaf, S. Francoz, P. Gasparini, A. Gobbi, K. Helin, P.G. Pelicci, A.G. Jochemsen, J.C. Marine, Amplification of Mdmx (or Mdm4) directly contributes to tumor formation by inhibiting p53 tumor suppressor activity. Mol Cell Biol 24, 5835–5843 (2004)CrossRefPubMedPubMedCentral
13.
H. Wang, C. Yan, A small-molecule p53 activator induces apoptosis through inhibiting MDMX expression in breast cancer cells. Neoplasia 13, 611–619 (2011)CrossRefPubMedPubMedCentral
14.
M.J. Riemenschneider, C.B. Knobbe, G. Reifenberger, Refined mapping of 1q32 amplicons in malignant gliomas confirms MDM4 as the main amplification target. Int J Cancer 104, 752–757 (2003)CrossRefPubMed
15.
X. Han, G. Garcia-Manero, T.J. McDonnell, G. Lozano, L.J. Medeiros, L. Xiao, G. Rosner, M. Nguyen, M. Fernandez, Y.A. Valentin-Vega, J. Barboza, D.M. Jones, G.Z. Rassidakis, H.M. Kantarjian, C.E. Bueso-Ramos, HDM4 (HDMX) is widely expressed in adult pre-B acute lymphoblastic leukemia and is a potential therapeutic target. Mod Pathol 20, 54–62 (2007)CrossRefPubMed
16.
Y.A. Valentin-Vega, J.A. Barboza, G.P. Chau, A.K. El-Naggar, G. Lozano, High levels of the p53 inhibitor MDM4 in head and neck squamous carcinomas. Hum Pathol 38, 1553–1562 (2007)CrossRefPubMedPubMedCentral
17.
T. Sun, G.S. Lee, W.K. Oh, M. Pomerantz, M. Yang, W. Xie, M.L. Freedman, P.W. Kantoff, Single-nucleotide polymorphisms in p53 pathway and aggressiveness of prostate cancer in a Caucasian population. Clin Cancer Res 16, 5244–5251 (2010)CrossRefPubMedPubMedCentral
18.
R. Tirabosco, G. De Maglio, M. Skrap, G. Falconieri, S. Pizzolitto, Expression of the Polycomb-group protein BMI1 and correlation with p16 in astrocytomas an immunohistochemical study on 80 cases. Pathol Res Pract 204, 625–631 (2008)CrossRefPubMed
19.
D. Li, D.Q. Li, D. Liu, X.J. Tang, MiR-613 induces cell cycle arrest by targeting CDK4 in non-small cell lung cancer. Cell Oncol 39, 139–147 (2016)CrossRef
20.
21.
Q. Li, G. Lozano, Molecular pathways: Targeting Mdm2 and Mdm4 in cancer therapy. Clin Cancer Res 19, 34–41 (2013)CrossRefPubMed
22.
J. Parant, A. Chavez-Reyes, N.A. Little, W. Yan, V. Reinke, A.G. Jochemsen, G. Lozano, Rescue of embryonic lethality in Mdm4-null mice by loss of Trp53 suggests a nonoverlapping pathway withMDM2 to regulate p53. Nat Genet 29, 92–95 (2001)CrossRefPubMed
23.
G. Jin, S. Cook, B. Cui, W.C. Chen, S.T. Keir, P. Killela, C. Di, C.A. Payne, S.G. Gregory, R. McLendon, D.D. Bigner, H. Yan, HDMX regulates p53 activity and confers chemoresistance to 3-bis(2-chloroethyl)-1-nitrosourea. Neuro-Oncology 12, 956–966 (2010)CrossRefPubMedPubMedCentral
24.
S. Haupt, D. Buckley, J.M. Pang, J. Panimaya, P.J. Paul, C. Gamell, E.A. Takano, Y.Y. Lee, S. Hiddingh, T.M. Rogers, A.F. Teunisse, M.J. Herold, J.C. Marine, S.B. Fox, A. Jochemsen, Y. Haupt, Targeting Mdmx to treat breast cancers with wild-type p53. Cell Death Dis 6, e1821 (2015)CrossRefPubMedPubMedCentral
25.
K. Heminger, M. Markey, M. Mpagi, S.J. Berberich, Alterations in gene expression and sensitivity to genotoxic stress following HdmX or Hdm2 knockdown in human tumor cells harboring wild-type p53. Aging 1, 89–108 (2009)CrossRefPubMedPubMedCentral
26.
Q. Yu, Y. Li, K. Mu, Z. Li, Q. Meng, X. Wu, Y. Wang, L. Li, Amplification of Mdmx and overexpression of MDM2 contribute to mammary carcinogenesis by substituting for p53 mutations. Diagn Pathol 9, 71 (2014)CrossRefPubMedPubMedCentral
27.
L. Marcar, B. Ihrig, J. Hourihan, S.E. Bray, P.R. Quinlan, L.B. Jordan, A.M. Thompson, T.R. Hupp, D.W. Meek, MAGE-A cancer/testis antigens inhibit MDM2 ubiquitylation function and promote increased levels of MDM4. PLoS One 10, e0127713 (2015)CrossRefPubMedPubMedCentral
28.
A.M. Carrillo, A. Bouska, M.P. Arrate, C.M. Eischen, Mdmx promotes genomic instability independent of p53 and Mdm2. Oncogene 34, 846–856 (2015)CrossRefPubMed
29.
30.
M. Shadfan, V. Lopez-Pajares, Z.M. Yuan, MDM2 and MDMX: Alone and together in regulation of p53. Transl Cancer Res 1, 88–89 (2012)PubMedPubMedCentral
31.
V. Sulzyc-Bielicka, P. Domagala, D. Bielicki, K. Safranow, W. Domagala, Thymidylate synthase expression and p21(WAF1)/p53 phenotype of colon cancers identify patients who may benefit from 5-fluorouracil based therapy. Cell Oncol 37, 17–28 (2014)CrossRef
Metadata
Title
MDMX is a prognostic factor for non-small cell lung cancer and regulates its sensitivity to cisplatin
Authors
Han Zhao
Yu-Zhuo Xie
Rui Xing
Ming Sun
Feng Chi
Yue-Can Zeng
Publication date
01-08-2017
Publisher
Springer Netherlands
Published in
Cellular Oncology / Issue 4/2017
Print ISSN: 2211-3428
Electronic ISSN: 2211-3436
DOI
https://doi.org/10.1007/s13402-017-0325-9

Other articles of this Issue 4/2017

Cellular Oncology 4/2017 Go to the issue

Report

Tumor cells interact with red blood cells via galectin-4 - a short report

Original Paper

The role of hERG1 ion channels in epithelial-mesenchymal transition and the capacity of riluzole to reduce cisplatin resistance in colorectal cancer cells

Original Paper

Involvement of the DNA mismatch repair system in cisplatin sensitivity of testicular germ cell tumours

Original Paper

microRNA-371a-3p as informative biomarker for the follow-up of testicular germ cell cancer patients

Report

Progesterone suppresses the invasion and migration of breast cancer cells irrespective of their progesterone receptor status - a short report

Original Paper

Association between epidermal growth factor receptor amplification and ADP-ribosylation factor 1 methylation in human glioblastoma
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits